Spaarne Gasthuis Stichting

Research site

The Netherlands Boerhaavelaan 22, 2035 RC Haarlem, The Netherlands

12 trials recruiting
Arteriosclerosis · Obesity · Chronic obstructive pulmonary disease
Adult patients

About Specializations

Spaarne Gasthuis Stichting in Haarlem, The Netherlands specialises in clinical trials of conditions such as Arteriosclerosis, Obesity, Chronic obstructive pulmonary disease, Atrial fibrillation, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Boerhaavelaan 222035 RC HaarlemThe Netherlands

Open in maps ↗

Recruiting now: 12 trials
Conditions studied: 22

More sites in Haarlem The Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

18 clinical trials

Arteriosclerosis

Recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Arteriosclerosis

Recruiting

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Arteriosclerosis

Recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pelacarsen
Sponsor:Novartis Pharma AG

Contact Research Centre

Atrial fibrillation

Recruiting

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:AP31969 sulfate
Sponsor:Acesion Pharma ApS

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Cerebrovascular accident

Recruiting

Study on Stopping or Continuing Clopidogrel, Carbasalate Calcium, and Dipyridamole for Young Patients After Stroke Without a Known Cause

Registered drugNo placebo

Study on Stopping or Continuing Clopidogrel, Carbasalate Calcium, and Dipyridamole for Young Patients After Stroke Without a Known Cause

Registered drugNo placebo

The Netherlands

Participants:18–64 years
Substances:Acetylsalicylic Acid
Sponsor:Stichting Radboud universitair medisch centrum

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Study on Adding Trastuzumab and Pertuzumab to Treatment for Patients with Resectable HER2 Positive Esophageal Cancer

Registered drugNo placebo

Study on Adding Trastuzumab and Pertuzumab to Treatment for Patients with Resectable HER2 Positive Esophageal Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pertuzumab
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Colorectal cancer metastatic+2

Recruiting

Study on the Effectiveness of Floxuridine and Drug Combination for Patients with Unresectable Colorectal Liver Metastases

Registered drugNo placebo

Study on the Effectiveness of Floxuridine and Drug Combination for Patients with Unresectable Colorectal Liver Metastases

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Prostate cancer

Recruiting

Study on Shortened Treatment with Apalutamide and Enzalutamide for Patients with Low-Volume Metastatic Castration-Sensitive Prostate Cancer

Registered drugNo placebo

Study on Shortened Treatment with Apalutamide and Enzalutamide for Patients with Low-Volume Metastatic Castration-Sensitive Prostate Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Apalutamide
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Dementia+1

Recruiting

Study on the Use of Flortaucipir for Diagnosing Mild Cognitive Impairment and Dementia in Patients

InvestigationalNo placebo

Study on the Use of Flortaucipir for Diagnosing Mild Cognitive Impairment and Dementia in Patients

InvestigationalNo placebo

The Netherlands

Participants:65+ years
Substances:Flortaucipir (18F)
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites